Assay Detail
Binding
CHEMBL4705508
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Inhibition of human ALK L1196M mutant expressed Sf9 cells pre-incubated for 30 mins before addition of Ulight-CKKSRGDYMTMQIG substrate and measured after 90 mins by fluorescence based assay
4
Total Activities
4
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Binding |
| Organism | Homo sapiens |
| Cell Type | Sf9 |
| Confidence | 9 — Direct single protein target |
| Curated By | Autocuration |
Publication
Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| IC50 | 4 | 7.95 | 8.96 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL2403108 | CERITINIB | 4.0 | 1 | 8.96 |
| CHEMBL1738797 | ALECTINIB | 4.0 | 1 | 8.82 |
| CHEMBL4764610 | — | — | 1 | 8.20 |
| CHEMBL601719 | CRIZOTINIB | 4.0 | 1 | 5.81 |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL2403108 | CERITINIB | IC50 | = | 1.1 | nM | 8.96 |
| CHEMBL1738797 | ALECTINIB | IC50 | = | 1.5 | nM | 8.82 |
| CHEMBL4764610 | — | IC50 | = | 6.3 | nM | 8.20 |
| CHEMBL601719 | CRIZOTINIB | IC50 | = | 1540.0 | nM | 5.81 |